Phathom Pharmaceuticals/$PHAT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Phathom Pharmaceuticals
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Ticker
$PHAT
Sector
Primary listing
Employees
427
Headquarters
Website
PHAT Metrics
BasicAdvanced
$940M
-
-$3.80
0.44
-
Price and volume
Market cap
$940M
Beta
0.44
52-week high
$17.94
52-week low
$2.21
Average daily volume
1.3M
Financial strength
Current ratio
2.231
Quick ratio
2.05
Long term debt to equity
-132.108
Total debt to equity
-138.009
Interest coverage (TTM)
-3.04%
Profitability
EBITDA (TTM)
-212.777
Gross margin (TTM)
87.25%
Net profit margin (TTM)
-186.53%
Operating margin (TTM)
-145.03%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
-42.54%
Return on equity (TTM)
90.07%
Valuation
Price to revenue (TTM)
6.62
Price to book
-2.27
Price to tangible book (TTM)
-2.27
Price to free cash flow (TTM)
-4.323
Free cash flow yield (TTM)
-23.13%
Free cash flow per share (TTM)
-3.12
Growth
Revenue change (TTM)
460.30%
Earnings per share change (TTM)
-33.10%
3-year earnings per share growth (CAGR)
-6.63%
What the Analysts think about PHAT
Analyst ratings (Buy, Hold, Sell) for Phathom Pharmaceuticals stock.
Bulls say / Bears say
Sequential revenue growth with Q3 2025 net revenues of $49.5 million, up 25% quarter-over-quarter driven by VOQUEZNA adoption (TipRanks).
Operating expense discipline delivered a 43% quarter-over-quarter reduction in cash operating expenses and a 77% cut in net cash usage in Q3, bolstering the path toward profitability (Investing.com).
Pipeline diversification with the initiation of the Phase 2 pHalcon-EoE-201 trial for eosinophilic esophagitis expands the growth outlook beyond GERD (TipRanks).
Persistent unprofitability with a net loss of $200.1 million for the nine months ended September 30, 2025 and an accumulated deficit of $1.5 billion raise sustainability concerns (StockTitan).
Elevated general and administrative expenses of $94.5 million in Q1 2025, up from $62.0 million a year earlier, highlight ongoing high fixed costs that could pressure margins (NASDAQ).
Significant reliance on a single approved product, VOQUEZNA, with only early-stage pipeline assets creates concentration risk if commercial or clinical setbacks occur (TipRanks).
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
PHAT Financial Performance
Revenues and expenses
PHAT Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Phathom Pharmaceuticals stock?
Phathom Pharmaceuticals (PHAT) has a market cap of $940M as of November 06, 2025.
What is the P/E ratio for Phathom Pharmaceuticals stock?
The price to earnings (P/E) ratio for Phathom Pharmaceuticals (PHAT) stock is 0 as of November 06, 2025.
Does Phathom Pharmaceuticals stock pay dividends?
No, Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next Phathom Pharmaceuticals dividend payment date?
Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders.
What is the beta indicator for Phathom Pharmaceuticals?
Phathom Pharmaceuticals (PHAT) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.